K. Keltai

发表

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Electrosynthesized molecularly imprinted polyscopoletin nanofilms for human serum albumin detection.

K. Keltai, F. Scheller, R. E. Gyurcsányi, 2017, Analytica chimica acta.

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2018, Journal of the American College of Cardiology.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, The Lancet.

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Spiegelmers as potential receptors for cTnI diagnostics

K. Keltai, T. Mészáros, Zsuzsanna Szeitner, 2017 .

[New anticoagulants in the prevention and treatment of venous thromboembolism].

K. Keltai, M. Keltai, 2011, Orvosi hetilap.

Endothelins: a Possible Mechanism of Cytostatics-induced Cardiomyopathy

K. Keltai, A. Rosta, I. Karádi, 2004, Leukemia & lymphoma.

Endothelin-1 and Cardiac Function in Anthracycline-treated Patients: A 1-year Follow-up

K. Keltai, A. Rosta, I. Karádi, 2004, Journal of cardiovascular pharmacology.

Effects of implantable cardioverter defibrillator implantation and shock application on serum endothelin-1 and big-endothelin levels.

K. Keltai, B. Merkely, A. Róka, 2002, Clinical science.

Endothelin Gene Expression During Ischemia and Reperfusion

K. Keltai, B. Merkely, H. Vágó, 2004, Journal of cardiovascular pharmacology.

Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.

Khalid Yusoff, Frederick M. Costello, Martin O'Donnell, 2017, Lancet.

Major Adverse Limb Events in Lower Extremity Peripheral Artery Disease: COMPASS Trial

Deepak L. Bhatt, S. Yusuf, K. Keltai, 2018 .

Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) Trial

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2018 .

Variations in Cause and Management of Atrial Fibrillation in a Prospective Registry of 15 400 Emergency Department Patients in 46 Countries: The RE-LY Atrial Fibrillation Registry

I. V. Van Gelder, S. Yusuf, Jun Zhu, 2014, Circulation.

Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline

Eric E. Smith, Deepak L. Bhatt, S. Yusuf, 2020, Stroke.

Stroke Outcomes in the COMPASS Trial

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2019, Circulation.

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial

Eric E. Smith, Deepak L. Bhatt, S. Yusuf, 2018, International journal of stroke : official journal of the International Stroke Society.

External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2018, European heart journal.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2017, The Canadian journal of cardiology.

Rationale , Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s ( COMPASS ) Trial

Donnell, Eld, Deepak L. Bhatt, 2017 .

Doxorubicin selectively suppresses mRNA expression and production of endothelin-1 in endothelial cells.

K. Keltai, Z. Doleschall, L. Cervenak, 2010, Vascular pharmacology.

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The Canadian journal of cardiology.

Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease.

S. Yusuf, J. Bosch, G. Dagenais, 2016, The New England journal of medicine.

Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial.

Deepak L. Bhatt, S. Yusuf, J. Bosch, 2022, European heart journal. Cardiovascular pharmacotherapy.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.

Effect of Incessant Ventricular Tachyarrhythmias on Serum Endothelin and Big-endothelin Levels

K. Keltai, B. Merkely, S. Szilágyi, 2004, Journal of cardiovascular pharmacology.

Electrosynthesized molecularly imprinted polyscopoletin nanofilms for human serum albumin detection.

K. Keltai, F. Scheller, R. E. Gyurcsányi, 2017, Analytica chimica acta.

Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease

J. Bosch, K. Keltai, P. Verhamme, 2018 .